November 6, 2013
Unlike Other Biotechs, It Is Full Steam Ahead for Nuvilex
In a year where there have been quite a few misfires in the small biotech world, Nuvilex, Inc. (OTCQB – NVLX - $0.139 – Spec Buy) is a shining star. It seems that not a day goes by when a small to medium sized biotech stock does not take it on the chin. To be sure, the biotechnology industry is characterized as a marathon rather than a sprint. As a result, nearly all companies succumb to fits and starts along the development process. It is practically a routine event considering it can happen with some frequency.
In Nuvilex’s case, one would be hard pressed to argue against the series of positive developments that have occurred, which have launched the Company’s stock to a settling point in the teens. And, with more good news in the offing, the stock appears poised to hit new highs. Already this year the Company has acquired rights to groundbreaking live-cell encapsulation technology to treat cancer that has completed clinical trials, raised $1.25 million at a premium to the market with limited dilution, reduced debt by more than $2 million and has made material progress in its plan to launch advanced clinical trials.
Earlier this week, Nuvilex announced that cloning of the cancer-drug-activating cells required for Nuvilex's future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities. Following receipt by Inno Biologics of four vials of frozen cells capable of converting the well-known anticancer prodrug ifosfamide into its active cancer-killing form, one of the vials was thawed and the cells grown in culture. The cells, which were previously grown by ViruSure in Vienna, were successfully thawed, and approximately 97% of the cells were found to be viable. The best clones will be propagated to obtain large numbers of cells required for the late-phase clinical trials of Nuvilex.
With each small step forward, the risk in these shares decreases and the value of the stock increases. However, when major steps such as the closing of the previously announced diabetes acquisition occurs, incremental moves higher should be replaced by major reductions in risk and an associated substantial increase in value, reflecting the new, large opportunity.
For more information, refer to our previous sponsored NVLX Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com